Not all individuals with CLL demand therapy. Even with all current improvements, the iwCLL even now recommends watchful observation for patients with asymptomatic illness.86 This suggestion is predicated on no less than two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (F